Back to search

Harokopio University

Επίδραση διατροφικής παρέμβασης με γιαούρτι (εμπλουτισμένο ή μη) σε γενικό πληθυσμό σε κλασικούς και νεότερους καρδιομεταβολικούς παράγοντες

Abstract

dc:description

Oxidative stress, inflammation, and thrombosis are fundamental mechanisms involved in the pathogenesis of cardiovascular diseases. Platelet-Activating Factor (PAF) is a potent mediator of these processes, and its regulation is influenced by both endogenous and dietary factors. The aim of this randomized clinical trial was to investigate the effect of daily consumption of plain and enriched yogurt containing polar lipids from olive pomace on markers of inflammation, oxidative stress, thrombosis, and on PAF metabolism. The study included 92 apparently healthy adults (35–65 years, BMI 20–35 kg/m²), who were randomized into three groups: group A (control group), group B (1 plain yogurt/day, 150 g), and group C (1 enriched yogurt/day, 150 g, containing 0.4% polar lipids from olive pomace). The intervention lasted 8 weeks, with biological samples collected at baseline, 4, and 8 weeks. Inflammatory markers (IL-6, IL-10, CRP, adiponectin), oxidative stress markers (GPx, TBARS, lag-time), hemostatic factors (PAI-1, tPA), and enzymes of PAF metabolism (PAF-CPT, two Lyso-PAF-AT isoforms, Lp-PLA2, PAF-AH) were assessed. Statistical evaluation was performed using both per protocol (PP) and intention-to-treat (ITT) analyses.In the PP analysis, plain yogurt consumption was associated with a reduction in GPx (p = 0.021 vs. control, p = 0.008 vs. enriched yogurt) and PAF-CPT activity (p = 0.038 at 8 weeks vs. control), suggesting a suppressive effect on antioxidant defense and de novo PAF biosynthesis. In contrast, enriched yogurt consumption was associated with decreased IL-10 levels and increased PAF EC50 (p = 0.021 vs. control), indicating reduced platelet sensitivity to PAF-induced aggregation. The ITT analysis confirmed the reduction in IL-10 (p = 0.022 at 4 weeks, p = 0.024 at 8 weeks) and revealed significantly lower IL-6 levels in the enriched yogurt group compared with the plain yogurt group at 4 weeks (p = 0.03). Moreover, enriched yogurt consumption was associated with a consistent increase in PAF EC50 at 4 and 8 weeks (p = 0.001 and p = 0.009, respectively), further supporting its anti-platelet effect. The consumption of plain yogurt led to a reduction in systolic blood pressure at both 4 and 8 weeks (p=0.023 and p= 0.004, respectively). At week 4 of the study, PAF-CPT specific activity of the participants who received the enriched yogurt was lower than the corresponding one of the participants in the control group (p=0.023) while at week 8 of the study, PAF-CPT specific activity of the participants who consumed either the enriched yogurt or the plain yogurt was lower than the PAF-CPT activity in the control group (p=0.043 and p=0.048, respectively). In addition, the intake of the enriched yogurt resulted in lower LpPLA2-to-LDL ratio at 8 weeks compared to the plain yogurt (p = 0.010). In conclusion, plain yogurt consumption was linked to reductions in GPx and systolic blood pressure, while enriched yogurt consumption resulted in significant decreases in IL-10 and IL-6 and an increase in PAF EC50, indicating anti-inflammatory and anti-platelet effects. The intake of both types of yogurt significantly reduced de novo PAF biosynthesis. These findings support the potential role of enriched yogurt as a functional food with cardioprotective properties.

Degree

thesis:*
Grantor dc:publisher
Harokopio University
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ntetopoulou, Maria
  • Ντετοπούλου, Μαρία

Subjects

dc:subject × 26

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/62329

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ntetopoulou, Maria; Ντετοπούλου, Μαρία. Επίδραση διατροφικής παρέμβασης με γιαούρτι (εμπλουτισμένο ή μη) σε γενικό πληθυσμό σε κλασικούς και νεότερους καρδιομεταβολικούς παράγοντες. Harokopio University, 2026. http://hdl.handle.net/10442/hedi/62329